Briefing
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
The final MASTER report describes using next-generation sequencing minimal residual disease after each phase of daratumumab, carfilzomib, lenalidomide, and dexamethasone to modulate treatment and stopping.
- Design: Evidence level 1
- Assay: NGS
The Lancet HaematologyPubMed 37776872DOI 10.1016/S2352-3026(23)00236-3